Pure Global AI
NCT06363435Recruiting

AI-based Measurements of Tumour Burden in PSMA PET-CT

The Prognostic Value of AI-based Measurements of Tumour Burden in PSMA PET-CT in Patients With Prostate Cancer
Elin TragardhClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Prostate Cancer
Drug/Device/Intervention
AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
Elin Tragardh
Funder
Skane University Hospital
Location
Lund,Malmö, Sweden
Timeline & enrollment
Phase
N/A
Start date
Mar 29, 2024
End date
Mar 01, 2033
Enrollment
1500 participants
Primary outcome

Tumour burden (cm3) in relation to overall survival

Summary

The primary aim of the present study is to evaluate how automatically calculated (by an
 AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x
 SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as
 the total tumour burden predicts overall survival (OS) in patients with prostate cancer
 (newly diagnosed and patients with biochemical recurrence).

ICD-10 classifications
Malignant neoplasm of prostateHyperplasia of prostateDisorder of prostate, unspecifiedOther disorders of prostateCarcinoma in situ: Prostate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06363435
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06363435 through Pure Global AI's free database. This phase not specified trial is sponsored by Elin Tragardh and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 1500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.